Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AbbVie has beefed up its neuro pipeline by acquiring Belgium-based Syndesi Therapeutics. This acquisition gives AbbVie access to Syndesi’s lead candidate SDI-118, a small molecule that is under evaluation to treat Alzheimer’s disease and major depressive disorder.
Lead Product(s): SDI-118
Therapeutic Area: Neurology Product Name: SDI-118
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $1,000.0 million Upfront Cash: $130.0 million
Deal Type: Acquisition March 01, 2022